Mechanisms of resistance to CAR T cell therapies.

[1]  D. Torigian,et al.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  H. Einsele,et al.  The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells , 2019, Science Translational Medicine.

[3]  A. Moody,et al.  HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases , 2019, Cancer Gene Therapy.

[4]  Jeremy D. Goldhaber-Fiebert,et al.  Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. P. Schroeder,et al.  PS942 CD19 MUTATION FREQUENCY AFTER BLINATUMOMAB TREATMENT IS LOWER THAN AFTER CAR T-CELLS TREATMENT , 2019, HemaSphere.

[6]  Weiss,et al.  B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , 2019, The Journal of clinical investigation.

[7]  Yuan-fang Liu,et al.  Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma , 2019, Proceedings of the National Academy of Sciences.

[8]  S. Grupp,et al.  Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. , 2019, Cancer discovery.

[9]  M. Sadelain,et al.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.

[10]  Juliet Investigators.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019 .

[11]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[12]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[13]  C. June,et al.  Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas , 2018, Blood.

[14]  A. Jakubowiak,et al.  JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE) , 2018, Blood.

[15]  M. Weitzman,et al.  CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis , 2018, Blood.

[16]  E. Ostertag,et al.  Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) , 2018, Blood.

[17]  Amanda M Li,et al.  Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia , 2018, Blood.

[18]  D. Maloney,et al.  Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma , 2018, Blood.

[19]  M. Stetler-Stevenson,et al.  Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22 , 2018, Molecular therapy oncolytics.

[20]  H. Mirzaei,et al.  Construction and functional characterization of a fully human anti‐CD19 chimeric antigen receptor (huCAR)‐expressing primary human T cells , 2018, Journal of cellular physiology.

[21]  Hua Jiang,et al.  Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma , 2018, Front. Pharmacol..

[22]  Hans Bitter,et al.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia , 2018, Nature Medicine.

[23]  Tyler J. Reich,et al.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell , 2018, Nature Medicine.

[24]  Zev A. Binder,et al.  Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas , 2018, Molecular therapy oncolytics.

[25]  R. Gottardo,et al.  Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) , 2018, Clinical Trials.

[26]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[27]  K. Yong,et al.  An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. , 2018, Blood.

[28]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[29]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[30]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[31]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[32]  M. Sabatino,et al.  Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells , 2017, Journal of Translational Medicine.

[33]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[34]  S. Riddell,et al.  Fully human CD19-specific chimeric antigen receptors for T-cell therapy , 2017, Leukemia.

[35]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[36]  H. Tony,et al.  Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. , 2017, Blood.

[37]  H. Heslop,et al.  Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  R. Rosenquist,et al.  T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers , 2016, Haematologica.

[39]  S. Grupp,et al.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.

[40]  M. Ebinger,et al.  T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts , 2016, Oncotarget.

[41]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[42]  J. Khan,et al.  CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity , 2016, Nature Communications.

[43]  M. Sabatino,et al.  Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. , 2016, Cytotherapy.

[44]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[45]  D. Maloney,et al.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.

[46]  C. Baldari,et al.  Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release. , 2016, Cell reports.

[47]  J. Byrd,et al.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.

[48]  S. Razavi,et al.  Immune Evasion Strategies of Glioblastoma , 2016, Front. Surg..

[49]  S. Grupp,et al.  Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies , 2016, Science Translational Medicine.

[50]  H. Einsele,et al.  Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. , 2015, Blood.

[51]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[52]  C. Desmarais,et al.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. , 2015, Blood.

[53]  E. Wherry,et al.  T cell exhaustion during persistent viral infections. , 2015, Virology.

[54]  K. Curran,et al.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[56]  T. Naoe,et al.  Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells , 2015, The Journal of Immunology.

[57]  Harjeet Singh,et al.  Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor , 2015, Cancer Gene Therapy.

[58]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Gina Zini,et al.  Diagnosis and Subclassification of Acute Lymphoblastic Leukemia , 2014, Mediterranean journal of hematology and infectious diseases.

[60]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[61]  Crystal Mackall,et al.  Simplified process for the production of anti-CD19-CAR-engineered T cells. , 2013, Cytotherapy.

[62]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[63]  J. Gribben,et al.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. , 2013, Blood.

[64]  J. Gribben,et al.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.

[65]  L. Koenderman,et al.  Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences , 2013, Cellular and Molecular Life Sciences.

[66]  D. Rossi,et al.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia , 2012, Haematologica.

[67]  D. Spaner,et al.  Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. , 2012, Cancer research.

[68]  J. Gribben,et al.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.

[69]  M. Ergin,et al.  Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature , 2012, Medical Oncology.

[70]  D. Mertens,et al.  Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia , 2012, PloS one.

[71]  Christopher M. Jackson,et al.  Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.

[72]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[73]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[74]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[75]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[76]  George Georgiou,et al.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.

[77]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[78]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[79]  G. Koretzky,et al.  T cell activation. , 2009, Annual review of immunology.

[80]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[81]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[83]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[85]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[86]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[87]  M. Yellin,et al.  T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. , 1994, Journal of immunology.

[88]  D. Campana,et al.  Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia , 1993, The Journal of experimental medicine.

[89]  G. Delespesse,et al.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression , 1992, The Journal of experimental medicine.

[90]  S. Sallan.  Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. , 2006, Hematology. American Society of Hematology. Education Program.

[91]  N. Kay,et al.  Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? , 1994, Leukemia.

[92]  R. Foà,et al.  Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. , 1985, Blood.